p27 (also known as KIP1, and encoded by CDKN1B) is regulated by multiple signal transduction pathways in normal and malignant cells. CDKN1B transcription can be regulated by the FoxO family and ...

Unlocking the potential of next-generation breast cancer treatments “The emergence of CDK inhibitors for the treatment of breast cancer has been pivotal in improving the standard of care for ...

Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...